Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
|
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 50 条
  • [31] Resistance in gastrointestinal stromal tumors
    Seeber, Andreas
    Perathoner, Alexander
    Kocher, Florian
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2019, 12 (02) : 140 - 143
  • [32] Genotyping and immunohistochemistry of gastrointestinal stromal tumors: An update
    Rubin, Brian P.
    Heinrich, Michael C.
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2015, 32 (05) : 392 - 399
  • [33] Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
    Rusakiewicz, Sylvie
    Semeraro, Michaela
    Sarabi, Matthieu
    Desbois, Melanie
    Locher, Clara
    Mendez, Rosa
    Vimond, Nadege
    Concha, Angel
    Garrido, Federico
    Isambert, Nicolas
    Chaigneau, Loic
    Le Brun-Ly, Valerie
    Dubreuil, Patrice
    Cremer, Isabelle
    Caignard, Anne
    Poirier-Colame, Vichnou
    Chaba, Kariman
    Flament, Caroline
    Halama, Niels
    Jaeger, Dirk
    Eggermont, Alexander
    Bonvalot, Sylvie
    Commo, Frederic
    Terrier, Philippe
    Opolon, Paule
    Emile, Jean-Francois
    Coindre, Jean-Michel
    Kroemer, Guido
    Chaput, Nathalie
    Le Cesne, Axel
    Blay, Jean-Yves
    Zitvogel, Laurence
    CANCER RESEARCH, 2013, 73 (12) : 3499 - 3510
  • [34] Frequence, Spectrum and Prognostic Impact of Additional Malignancies in Patients With Gastrointestinal Stromal Tumors
    Kramer, K.
    Wolf, S.
    Mayer, B.
    Schmidt, S. A.
    Agaimy, A.
    Henne-Bruns, D.
    Knippschild, U.
    Schwab, M.
    Schmieder, M.
    NEOPLASIA, 2015, 17 (01): : 134 - 140
  • [35] Identification of prognostic factors in patients with metastatic gastrointestinal stromal tumors
    Cubukcu, E.
    Olmez, O. F.
    Avci, N.
    Canhoroz, M.
    Kurt, E.
    Kanat, O.
    Evrensel, T.
    Manavoglu, O.
    JOURNAL OF BUON, 2012, 17 (03): : 517 - 521
  • [36] Midkine as a prognostic marker for gastrointestinal stromal tumors
    Kaifi, Jussuf T.
    Fiegel, Henning C.
    Rafnsdottir, Svanheidur L.
    Aridome, Kuniaki
    Schurr, Paulus G.
    Reichelt, Uta
    Wachowiak, Robin
    Kleinhans, Helge
    Yekebas, Emre F.
    Mann, Oliver
    Ichihara-Tanaka, Keiko
    Muramatsu, Takashi
    Kluth, Dietrich
    Strate, Tim
    Izbicki, Jakob R.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (07) : 431 - 435
  • [37] Midkine as a prognostic marker for gastrointestinal stromal tumors
    Jussuf T. Kaifi
    Henning C. Fiegel
    Svanheidur L. Rafnsdottir
    Kuniaki Aridome
    Paulus G. Schurr
    Uta Reichelt
    Robin Wachowiak
    Helge Kleinhans
    Emre F. Yekebas
    Oliver Mann
    Keiko Ichihara-Tanaka
    Takashi Muramatsu
    Dietrich Kluth
    Tim Strate
    Jakob R. Izbicki
    Journal of Cancer Research and Clinical Oncology, 2007, 133 : 431 - 435
  • [38] Prognostic factors for dogs with surgically resected gastrointestinal stromal tumors
    Irie, Mitsuhiro
    Tomiyasu, Hirotaka
    Tsujimoto, Hajime
    Kita, Chiaki
    Kagawa, Yumiko
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (09) : 1481 - 1484
  • [39] Optimal thresholds of risk parameters for gastrointestinal stromal tumors
    Sander, Bjoern
    Cameron, Silke
    Gunawan, Bastian
    Fuezesi, Laszlo
    EJSO, 2020, 46 (01): : 180 - 188
  • [40] Outcomes of Patients with Gastrointestinal Stromal Tumors in the Past Decade
    Bangolo, Ayrton
    Fwelo, Pierre
    Al-Qatish, Tha'er
    Bukasa-Kakamba, John
    Lee, Tiffany
    Cayago, Akira G.
    Potiguara, Sarah
    Nagesh, Vignesh K.
    Kawall, Jessica
    Ahmed, Rashid
    Abbas, Muhammad Asjad
    Nursjamsi, Narissa
    Lee, Stacy H.
    Meti, Shagi
    Arana, Georgemar V.
    Joseph, Chrishanti A.
    Mohamed, Abdifitah
    Alencar, Arthur
    Hassan, Huzaifa G.
    Aryal, Pramanu
    Javed, Aleena
    Kalinin, Maksim
    Lawal, Gbenga
    Khalaf, Ibtihal Y.
    Mathew, Midhun
    Karamthoti, Praveena
    Gupta, Bhavna
    Weissman, Simcha
    MEDICAL SCIENCES, 2023, 11 (03)